KC02 is a structural analog of KC01 and inactive form of KC01.
The synthesis of KC02 consistently yielded a 4:1 mixture of Z/E isomers, which proved difficult to chromatographically separate. By competitive gel-based ABPP assys, KC02 inhibited ABHD16A (human and mouse) with IC50 value of >10μM, while KC01 is in range of nM. By PS substrate assays, KC02 inhibited human ABHD16A with IC50 value of > 10μM, while KC01 is in range of nM.
Most of these enzymes were also inhibited by the control probe KC02, with the exception of two partial off-targets, ABHD3 and ABHD13. KC02 also inhibited ABHD11 (94%) and LYPLA1 (63%) but did not substantially inhibit ABHD16A (<30%). In situ treatment with KC01 (1μM, 4 h) but not KC02 (1μM, 4 h) blocked the PS lipase activity of membrane fractions from COLO205, K562 and MCF7 cell lines. KC01 and KC02 constitute a suitable pair of active and inactive (control) probes to investigate the function of ABHD16A in cellular systems. Treatment with KC01 but not KC02 (1μM, 4 h) substantially lowered secreted lyso-PSs of the ABHD12-null LCL. All LCLs also showed decreased cellular lyso-PSs following treatment with KC01 but not KC02. KC01 but not KC02 elevated PS lipase activity and reduced in lyso-PS lipase activity in LPS-stimulated macrophages. The LPS-induced increases in lyso-PS and cytokine secretion were both blocked by pretreatment of Abhd12−/− macrophages with KC01 (1μM, 4 h) but not KC02 (1μM, 4 h).
In COLO205 cells, 1μM KC01 but not KC02 showed substantial reductions in the levels of all detected cellular lyso-PSs compared to DMSO-treated control cells. The levels of secreted lyso-PSs (18:1 and 18:0) were also decreased in COLO205 cells treated with KC01 compared to those in KC02- or DMSO-treated cells (4-h treatments of cells in serum-free medium), whereas levels of other secreted lipids (lyso-PCs, lyso-PEs and MAGs) were unchanged across these treatment groups.
KC01, but not KC02, inhibited the PS lipase activity of brain membrane lysates from 2-month-old Abhd12+/+ and Abhd12−/− mice.
Reference:
1.Kamat SS, Camara K2, Parsons WH et al. Immunomodulatory lysophosphatidylserines are regulated by ABHD16A and ABHD12 interplay. Nat Chem Biol. 2015 Feb;11(2):164-71.
인용 문헌 (Citations)
현재 이 제품에 대한 인용 문헌이 없습니다. 아래는 GlpBio 제품을 인용한 주요 논문입니다.제품 설명 (Description)
제품 문서 (Product Documents)
Purity:>98.00%Appearance:A solid
화학적 특성 (Chemical Properties)
CAS 번호
1646795-60-9
화학명
6-(2-oxo-4-tridecyloxetan-3-yl)hexanamide
SMILES
CCCCCCCCCCCCCC1OC(C1CCCCCC(N)=O)=O
분자식
C22H41NO3
분자량
367.57
용해도
DMF: 5 mg/ml,DMSO: 5 mg/ml,Ethanol: 16 mg/ml,Ethanol:PBS(pH 7.2) (1:5): 0.5 mg/ml
보관
Store at -20°C
일반 주의사항
제품의 용해도 데이터에 따라 적절한 용매를 선택하십시오. 조제 후에는 반복적인 동결·해동을 피할 수 있도록 저장 용액을 소분하십시오.
저장 용액은 -80°C 보관 시 6개월 이내, -20°C 보관 시 1개월 이내에 사용하십시오.
용해도를 높이려면 튜브를 37°C로 데운 뒤 적절한 시간 동안 초음파 처리하십시오.
저장 용액은 -80°C 보관 시 6개월 이내, -20°C 보관 시 1개월 이내에 사용하십시오.
용해도를 높이려면 튜브를 37°C로 데운 뒤 적절한 시간 동안 초음파 처리하십시오.
배송 조건
평가용 샘플은 아이스팩과 함께 배송됩니다. 그 외 용량은 실온 배송되며, 요청 시 아이스팩과 함께 배송할 수 있습니다.
계산 도구 (Calculators)몰 농도 / 희석 / 분자량 / 단위 변환 / 생체 내 제형 / 용해도
g/mol
Reviews
Review for KC02
Rating: 5
- 5 Star100%
- 4 Star0%
- 3 Star0%
- 2 Star0%
- 1 Star0%
















